These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 23240729)
1. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. Balato N; Megna M; Di Costanzo L; Balato A; Ayala F Br J Dermatol; 2013 Jan; 168(1):201-5. PubMed ID: 23240729 [TBL] [Abstract][Full Text] [Related]
2. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944 [TBL] [Abstract][Full Text] [Related]
3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Spuls PI; Hooft L Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312 [TBL] [Abstract][Full Text] [Related]
4. Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis. Frühauf J; Schwantzer G; Ambros-Rudolph CM; Weger W; Ahlgrimm-Siess V; Salmhofer W; Hofmann-Wellenhof R Australas J Dermatol; 2012 Feb; 53(1):41-6. PubMed ID: 22309330 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160 [TBL] [Abstract][Full Text] [Related]
6. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. Vender R J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550 [TBL] [Abstract][Full Text] [Related]
7. An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial. Bostoen J; Bracke S; De Keyser S; Lambert J Br J Dermatol; 2012 Nov; 167(5):1025-31. PubMed ID: 22709422 [TBL] [Abstract][Full Text] [Related]
8. A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis. Ersser SJ; Cowdell FC; Nicholls PG; Latter SM; Healy E J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):738-45. PubMed ID: 21707770 [TBL] [Abstract][Full Text] [Related]
9. Perception of disease and doctor-patient relationship experienced by patients with psoriasis: a questionnaire-based study. Linder D; Dall'olio E; Gisondi P; Berardesca E; Gennaro ED; Pennella AR; Giannetti A; Peserico A; Girolomoni G Am J Clin Dermatol; 2009; 10(5):325-30. PubMed ID: 19658445 [TBL] [Abstract][Full Text] [Related]
10. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Bergstrom KG; Arambula K; Kimball AB Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784 [TBL] [Abstract][Full Text] [Related]
11. A telephone-based motivational interviewing intervention has positive effects on psoriasis severity and self-management: a randomized controlled trial. Larsen MH; Krogstad AL; Aas E; Moum T; Wahl AK Br J Dermatol; 2014 Dec; 171(6):1458-69. PubMed ID: 25143061 [TBL] [Abstract][Full Text] [Related]
12. A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. Bundy C; Pinder B; Bucci S; Reeves D; Griffiths CE; Tarrier N Br J Dermatol; 2013 Aug; 169(2):329-36. PubMed ID: 23551271 [TBL] [Abstract][Full Text] [Related]
13. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183 [TBL] [Abstract][Full Text] [Related]
14. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Jacobson CC; Kimball AB Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545 [TBL] [Abstract][Full Text] [Related]
15. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152 [TBL] [Abstract][Full Text] [Related]
16. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043 [TBL] [Abstract][Full Text] [Related]
17. The relationship between quality of life and the severity of psoriasis in Turkey. Çakmur H; Derviş E Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046 [TBL] [Abstract][Full Text] [Related]
18. Self-reported psoriasis severity and quality of life assessment at Comano spa. Pagliarello C; Calza A; Di Pietro C; Tabolli S Eur J Dermatol; 2012; 22(1):111-6. PubMed ID: 22063458 [TBL] [Abstract][Full Text] [Related]
19. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study. Daudén E; Herrera E; Puig L; Sánchez-Carazo JL; Toribio J; Perulero N Actas Dermosifiliogr; 2013 Oct; 104(8):685-93. PubMed ID: 23958428 [TBL] [Abstract][Full Text] [Related]
20. The role of community pharmacists in supporting self-management in patients with psoriasis. Tucker R; Stewart D Int J Pharm Pract; 2017 Apr; 25(2):140-146. PubMed ID: 27488688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]